Brian Abrahams
Stock Analyst at RBC Capital
(1.45)
# 3,204
Out of 4,829 analysts
445
Total ratings
35.65%
Success rate
-11.12%
Average return
Main Sectors:
Stocks Rated by Brian Abrahams
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics | Maintains: Sector Perform | $87 → $58 | $36.27 | +59.91% | 34 | May 7, 2025 | |
| PTCT PTC Therapeutics | Maintains: Outperform | $57 → $58 | $44.23 | +31.13% | 20 | May 7, 2025 | |
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Outperform | $65 → $58 | $6.45 | +799.22% | 8 | May 7, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Sector Perform | $420 → $423 | $424.99 | -0.47% | 52 | May 6, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Outperform | $137 → $145 | $115.71 | +25.31% | 19 | May 6, 2025 | |
| BCRX BioCryst Pharmaceuticals | Reiterates: Outperform | $11 → $13 | $9.97 | +30.39% | 18 | May 6, 2025 | |
| BIIB Biogen | Maintains: Outperform | $217 → $205 | $118.17 | +73.48% | 36 | May 2, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $1,051 → $943 | $527.78 | +78.67% | 31 | Apr 30, 2025 | |
| INCY Incyte | Maintains: Sector Perform | $64 → $67 | $58.98 | +13.60% | 21 | Apr 30, 2025 | |
| LEGN Legend Biotech | Reiterates: Outperform | $84 | $31.78 | +164.32% | 1 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $21 | $10.45 | +100.96% | 2 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $67 | $38.39 | +74.55% | 1 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $31 | $10.38 | +198.65% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $4 → $3 | $1.41 | +112.77% | 13 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $4 | $0.66 | +503.41% | 6 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $24 → $20 | $7.43 | +169.18% | 10 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $45 | $6.02 | +648.13% | 11 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $84 → $90 | $96.91 | -7.13% | 31 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $139 → $143 | $107.76 | +32.70% | 2 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $40 | $18.37 | +117.75% | 1 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $20 → $1.5 | $1.13 | +32.74% | 15 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $31 | $3.87 | +701.03% | 4 | Jan 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $4 → $1.5 | $0.40 | +275.28% | 5 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $48 → $2 | $1.30 | +53.85% | 11 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Sector Perform | $4 | $6.57 | -39.12% | 21 | Nov 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $32 → $30 | $25.31 | +18.53% | 11 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $55 | $35.02 | +57.05% | 13 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $13 → $12 | $7.71 | +55.74% | 14 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $22 | $6.15 | +257.72% | 9 | Jun 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $25 → $15 | $5.27 | +184.63% | 14 | Oct 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $12 → $9 | $1.39 | +547.48% | 3 | Mar 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $21 → $33 | $40.90 | -19.32% | 3 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $35.11 | - | 4 | Dec 4, 2017 |
Sarepta Therapeutics
May 7, 2025
Maintains: Sector Perform
Price Target: $87 → $58
Current: $36.27
Upside: +59.91%
PTC Therapeutics
May 7, 2025
Maintains: Outperform
Price Target: $57 → $58
Current: $44.23
Upside: +31.13%
Corbus Pharmaceuticals Holdings
May 7, 2025
Maintains: Outperform
Price Target: $65 → $58
Current: $6.45
Upside: +799.22%
Vertex Pharmaceuticals
May 6, 2025
Maintains: Sector Perform
Price Target: $420 → $423
Current: $424.99
Upside: -0.47%
Neurocrine Biosciences
May 6, 2025
Maintains: Outperform
Price Target: $137 → $145
Current: $115.71
Upside: +25.31%
BioCryst Pharmaceuticals
May 6, 2025
Reiterates: Outperform
Price Target: $11 → $13
Current: $9.97
Upside: +30.39%
Biogen
May 2, 2025
Maintains: Outperform
Price Target: $217 → $205
Current: $118.17
Upside: +73.48%
Regeneron Pharmaceuticals
Apr 30, 2025
Maintains: Outperform
Price Target: $1,051 → $943
Current: $527.78
Upside: +78.67%
Incyte
Apr 30, 2025
Maintains: Sector Perform
Price Target: $64 → $67
Current: $58.98
Upside: +13.60%
Legend Biotech
Apr 22, 2025
Reiterates: Outperform
Price Target: $84
Current: $31.78
Upside: +164.32%
Apr 1, 2025
Reiterates: Outperform
Price Target: $21
Current: $10.45
Upside: +100.96%
Mar 18, 2025
Initiates: Outperform
Price Target: $67
Current: $38.39
Upside: +74.55%
Mar 7, 2025
Initiates: Outperform
Price Target: $31
Current: $10.38
Upside: +198.65%
Mar 4, 2025
Maintains: Sector Perform
Price Target: $4 → $3
Current: $1.41
Upside: +112.77%
Mar 4, 2025
Reiterates: Sector Perform
Price Target: $4
Current: $0.66
Upside: +503.41%
Feb 21, 2025
Maintains: Sector Perform
Price Target: $24 → $20
Current: $7.43
Upside: +169.18%
Feb 20, 2025
Reiterates: Outperform
Price Target: $45
Current: $6.02
Upside: +648.13%
Feb 12, 2025
Maintains: Sector Perform
Price Target: $84 → $90
Current: $96.91
Upside: -7.13%
Feb 3, 2025
Maintains: Outperform
Price Target: $139 → $143
Current: $107.76
Upside: +32.70%
Jan 28, 2025
Reiterates: Outperform
Price Target: $40
Current: $18.37
Upside: +117.75%
Jan 10, 2025
Downgrades: Sector Perform
Price Target: $20 → $1.5
Current: $1.13
Upside: +32.74%
Jan 9, 2025
Reiterates: Outperform
Price Target: $31
Current: $3.87
Upside: +701.03%
Dec 20, 2024
Maintains: Sector Perform
Price Target: $4 → $1.5
Current: $0.40
Upside: +275.28%
Dec 20, 2024
Downgrades: Sector Perform
Price Target: $48 → $2
Current: $1.30
Upside: +53.85%
Nov 21, 2024
Upgrades: Sector Perform
Price Target: $4
Current: $6.57
Upside: -39.12%
Nov 1, 2024
Maintains: Sector Perform
Price Target: $32 → $30
Current: $25.31
Upside: +18.53%
Sep 3, 2024
Reiterates: Outperform
Price Target: $55
Current: $35.02
Upside: +57.05%
Aug 6, 2024
Maintains: Sector Perform
Price Target: $13 → $12
Current: $7.71
Upside: +55.74%
Jun 5, 2024
Reiterates: Outperform
Price Target: $22
Current: $6.15
Upside: +257.72%
Oct 2, 2023
Maintains: Sector Perform
Price Target: $25 → $15
Current: $5.27
Upside: +184.63%
Mar 31, 2022
Maintains: Sector Perform
Price Target: $12 → $9
Current: $1.39
Upside: +547.48%
Nov 3, 2021
Maintains: Sector Perform
Price Target: $21 → $33
Current: $40.90
Upside: -19.32%
Dec 4, 2017
Upgrades: Buy
Price Target: n/a
Current: $35.11
Upside: -